Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ...

Gregory M. Alushin, Michel C. Nussenzweig, and Jeffrey V. Ravetch Three Rockefeller researchers have been selected for the ...

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...

Scientists are reprogramming the immune system through cutting-edge approaches like CAR-T cells, engineered dendritic vaccines, AI-driven antibody design, and senolytic therapies, highlighting both ...

An international team led by researchers at Lund University in Sweden has identified the molecular tools needed to reprogram ordinary cells into specialised immune cells. The discovery, published in ...

In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the "recipe" for the transformation. Researchers at Lund University have now created ...

Digestive tract tumors are malignant diseases characterized by high aggressiveness, heterogeneity and metabolic abnormalities ...

A breakthrough in CAR-T therapy may allow cancer treatment with a single injection, cutting costs and making care more available.

Researchers are redesigning lipid nanoparticles to do more than shuttle mRNA into cells, with preclinical studies suggesting ...